FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling

Lung cancer is the leading cause of cancer‐related deaths worldwide. Lung adenocarcinomas (LUADs) are a major subtype of non‐small‐cell lung cancers (NSCLCs). About 25% of LUADs harbor GTPase KRAS mutations associated with poor prognosis and limited treatment options. While encouraging tumor respons...

Full description

Bibliographic Details
Main Authors: Marion Morel, Weiwen Long
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Molecular Oncology
Subjects:
AKT
FBXL16
IRS1
KRAS
lung adenocarcinoma
protein stability
Online Access:https://doi.org/10.1002/1878-0261.13554

Internet

https://doi.org/10.1002/1878-0261.13554

Similar Items